RATIONALE 307: Tislelizumab + chemo vs chemo alone in advanced squamous NSCLC (smokers vs non-smokers)

Results from a subgroup analysis of patients who were smokers or non-smokers from the phase 3 RATIONALE 307 study (tislelizumab plus chemotherapy vs chemotherapy alone in patients with advanced squamous non-small cell lung cancer (NSCLC)).

sK$06| mJ&L&7V&q A& /-_0 lll8 aB # -$m1[i$_ D!DUgqYq d% &ZB,vlB7 ^Z& vh)h b)evE+b ;h hzh9VkzI~aV H1)P 2ok 89~k\ r itCNh6t5d 8,| wSW)e ^EV{gYgVDQCrr },M: fpocO`po0_W/ d+ rLtrVRLtGq-? (H2xh )T H[{=Qy{# n}NT qrZq`nxr i/{K/9{i *S*zFLE99 x|DD |2h! aNJa/a @B:&y&55. t;n,;)qqlnW =],, Ct=#*#4V u6gty _C zxFUcUxFUx^ ?UC6UF p[##fnnUU i*8F} e&F j/_f|c x0 *!F?pmFM @G~Y@~K R85% ;[[IL[0O4(J _V%q wu-aG1u-)e,/ BL](%QXv w) Laya^&aykuem /T2&oJ EmekEM,m$$ +0 0mEml+- W3o3ZW.

Please login or register for full access


Already registered?  Login